Exome Asset Management LLC historic quarter change: USA Other Stocks, Sold out
In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 10 quarters from 2023-12-31 to 2026-06-30, Exome Asset Management LLC opened 17 positions, added to 4, reduced 6 and sold out of 29.
- Q1 2026: Stock WAVE LIFE SCIENCES LTD; Country of operation —; Class SHS; Shares before 421,488.
- Q4 2025: Stock IMMUNIC INC; Country of operation United States; Class COM; Shares before 173,900.
- Q3 2025: Stock VYNE THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 208,970.
- Q3 2025: Stock ELEVATION ONCOLOGY INC; Country of operation United States; Class COM; Shares before 110,353.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 2011932), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-13); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-15); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-16); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-10-03); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2023-12-31.
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q1 2026 | WAVE LIFE SCIENCES LTD
CUSIP Y95308105 | | SHS | 421,488 | 0 | -421,488 | $7,165,296 | $0 | -$7,165,296 | 2026-05-15 |
|---|
| Q4 2025 | IMMUNIC INC
CUSIP 4525EP101 | United States | COM | 173,900 | 0 | -173,900 | $153,310 | $0 | -$153,310 | 2026-02-13 |
|---|
| Q3 2025 | VYNE THERAPEUTICS INC
CUSIP 92941V308 | United States | COM | 208,970 | 0 | -208,970 | $344,801 | $0 | -$344,801 | 2025-11-14 |
|---|
| Q3 2025 | ELEVATION ONCOLOGY INC
CUSIP 28623U101 | United States | COM | 110,353 | 0 | -110,353 | $40,511 | $0 | -$40,511 | 2025-11-14 |
|---|
| Q2 2025 | NEKTAR THERAPEUTICS
CUSIP 640268108 | United States | COM | 2,232,453 | 0 | -2,232,453 | $1,518,068 | $0 | -$1,518,068 | 2025-08-15 |
|---|
| Q1 2025 | BLUEPRINT MEDICINES CORP
CUSIP 09627Y109 | United States | COM | 31,800 | 0 | -31,800 | $2,773,596 | $0 | -$2,773,596 | 2025-05-16 |
|---|
| Q1 2025 | VERU INC
CUSIP 92536C103 | United States | COM | 1,117,600 | 0 | -1,117,600 | $739,509 | $0 | -$739,509 | 2025-05-16 |
|---|
| Q1 2025 | ACELYRIN INC
CUSIP 00445A100 | United States | COM | 234,435 | 0 | -234,435 | $736,126 | $0 | -$736,126 | 2025-05-16 |
|---|
| Q1 2025 | MERSANA THERAPEUTICS INC
CUSIP 59045L106 | United States | COM | 172,924 | 0 | -172,924 | $249,723 | $0 | -$249,723 | 2025-05-16 |
|---|
| Q4 2024 | SPRINGWORKS THERAPEUTICS INC
CUSIP 85205L107 | | COM | 100,700 | 0 | -100,700 | $3,226,428 | $0 | -$3,226,428 | 2025-02-14 |
|---|
| Q4 2024 | REVANCE THERAPEUTICS INC
CUSIP 761330109 | United States | COM | 347,600 | 0 | -347,600 | $1,804,044 | $0 | -$1,804,044 | 2025-02-14 |
|---|
| Q3 2024 | WAVE LIFE SCIENCES LTD
CUSIP Y95308105 | | SHS | 488,135 | 0 | -488,135 | $2,435,794 | $0 | -$2,435,794 | 2024-11-14 |
|---|
| Q3 2024 | ELEVATION ONCOLOGY INC
CUSIP 28623U101 | United States | COM | 369,322 | 0 | -369,322 | $997,169 | $0 | -$997,169 | 2024-11-14 |
|---|
| Q2 2024 | ALPINE IMMUNE SCIENCES INC
CUSIP 02083G100 | United States | COM | 117,000 | 0 | -117,000 | $4,637,880 | $0 | -$4,637,880 | 2024-10-03 |
|---|
| Q2 2024 | AEROVATE THERAPEUTICS INC
CUSIP 008064107 | United States | COM | 98,485 | 0 | -98,485 | $2,912,201 | $0 | -$2,912,201 | 2024-10-03 |
|---|
| Q2 2024 | INOZYME PHARMA INC
CUSIP 45790W108 | United States | COM | 273,413 | 0 | -273,413 | $2,094,344 | $0 | -$2,094,344 | 2024-10-03 |
|---|
| Q2 2024 | MARINUS PHARMACEUTICALS INC
CUSIP 56854Q200 | United States | COM NEW | 163,100 | 0 | -163,100 | $1,474,424 | $0 | -$1,474,424 | 2024-10-03 |
|---|
| Q2 2024 | INARI MED INC
CUSIP 45332Y109 | United States | COM | 30,100 | 0 | -30,100 | $1,444,198 | $0 | -$1,444,198 | 2024-10-03 |
|---|
| Q2 2024 | INTRA-CELLULAR THERAPIES INC
CUSIP 46116X101 | United States | COM | 20,300 | 0 | -20,300 | $1,404,760 | $0 | -$1,404,760 | 2024-10-03 |
|---|
| Q2 2024 | SHOCKWAVE MED INC
CUSIP 82489T104 | United States | COM | 4,000 | 0 | -4,000 | $1,302,520 | $0 | -$1,302,520 | 2024-10-03 |
|---|
| Q2 2024 | REGULUS THERAPEUTICS INC
CUSIP 75915K309 | United States | COM | 402,504 | 0 | -402,504 | $1,159,212 | $0 | -$1,159,212 | 2024-10-03 |
|---|
| Q2 2024 | AVROBIO INC
CUSIP 05455M100 | United States | COM | 61,135 | 0 | -61,135 | $78,253 | $0 | -$78,253 | 2024-10-03 |
|---|
| Q1 2024 | IMMUNOGEN INC
CUSIP 45253H101 | United States | COM | 186,900 | 0 | -186,900 | $5,541,585 | $0 | -$5,541,585 | 2024-05-15 |
|---|
| Q1 2024 | INHIBRX INC
CUSIP 45720L107 | United States | COM | 73,158 | 0 | -73,158 | $2,780,004 | $0 | -$2,780,004 | 2024-05-15 |
|---|
| Q1 2024 | IGM BIOSCIENCES INC
CUSIP 449585108 | United States | COM | 135,596 | 0 | -135,596 | $1,126,803 | $0 | -$1,126,803 | 2024-05-15 |
|---|
| Q1 2024 | MIRATI THERAPEUTICS INC
CUSIP 60468T105 | United States | COM | 15,896 | 0 | -15,896 | $933,890 | $0 | -$933,890 | 2024-05-15 |
|---|
| Q1 2024 | SAGE THERAPEUTICS INC
CUSIP 78667J108 | United States | COM | 35,257 | 0 | -35,257 | $764,019 | $0 | -$764,019 | 2024-05-15 |
|---|
| Q1 2024 | SUTRO BIOPHARMA INC
CUSIP 869367102 | United States | COM | 153,600 | 0 | -153,600 | $658,944 | $0 | -$658,944 | 2024-05-15 |
|---|
| Q1 2024 | KINNATE BIOPHARMA INC
CUSIP 49705R105 | United States | COM | 83,848 | 0 | -83,848 | $198,720 | $0 | -$198,720 | 2024-05-15 |
|---|